A Phase II Trial of Dexamethasone, High-Dose Cytarabine, and Cisplatin (DHAP) in Combination with Rituximab as Salvage Treatment for Patients with Refractory or Relapsed Aggressive Non-Hodgkin’s Lymphoma.
Ulrich Mey(Kantonsspital Graubünden), Ingo G.H. Schmidt‐Wolf(University Hospital Bonn), Josef Birkmann(Paracelsus Medizinische Privatuniversität), Andreas Neubauer(RWTH Aachen University), Katjana Orlopp(University of Bonn), Anthony D. Ho(Heidelberg University), Ulrich Kaiser(University of Applied Sciences Landshut), Axel Glasmacher(University Hospital Bonn), Dimitri Flieger(Klinikum Aschaffenburg), John Strehl(University of Bonn)
Cited by 3
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
|The Lancet Oncology|2008|1.1k
Replicative Senescence of Mesenchymal Stem Cells: A Continuous and Organized Process
|PLoS ONE|2008|1.1k
Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)
|Journal of Clinical Oncology|2005|573